Elevance Health (NYSE:ELV) Issues Earnings Results

Elevance Health (NYSE:ELV) posted its earnings results on Wednesday. The company reported $7.45 earnings per share for the quarter, topping the consensus estimate of $6.18 by $1.27, Briefing.com reports. The firm had revenue of $49.83 billion during the quarter, compared to the consensus estimate of $48.84 billion. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The company’s revenue was up .8% on a year-over-year basis. During the same quarter last year, the company earned $8.84 earnings per share.

Elevance Health Stock Up 1.2%

ELV opened at $430.21 on Wednesday. The firm has a market capitalization of $93.42 billion, a P/E ratio of 18.30, a price-to-earnings-growth ratio of 2.41 and a beta of 0.67. Elevance Health has a one year low of $273.71 and a one year high of $436.24. The company has a fifty day moving average price of $399.37 and a 200-day moving average price of $354.74. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48.

Elevance Health Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, June 25th. Shareholders of record on Wednesday, June 10th were issued a $1.72 dividend. This represents a $6.88 annualized dividend and a yield of 1.6%. The ex-dividend date of this dividend was Wednesday, June 10th. Elevance Health’s dividend payout ratio (DPR) is presently 29.26%.

Insider Activity

In other news, Director Robert L. Dixon, Jr. sold 151 shares of Elevance Health stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $401.77, for a total transaction of $60,667.27. Following the completion of the sale, the director owned 10,734 shares in the company, valued at approximately $4,312,599.18. This trade represents a 1.39% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.34% of the company’s stock.

Institutional Investors Weigh In On Elevance Health

Institutional investors and hedge funds have recently bought and sold shares of the stock. Caden Capital Partners LP purchased a new stake in Elevance Health during the fourth quarter valued at about $101,000. Miller Capital Partners Inc. purchased a new position in shares of Elevance Health in the fourth quarter worth about $159,000. Ankerstar Wealth LLC bought a new stake in shares of Elevance Health in the 4th quarter valued at about $112,000. HM Payson & Co. boosted its holdings in Elevance Health by 15.0% during the 4th quarter. HM Payson & Co. now owns 437 shares of the company’s stock valued at $153,000 after acquiring an additional 57 shares during the period. Finally, Sepio Capital LP purchased a new stake in Elevance Health during the 4th quarter valued at about $201,000. 89.24% of the stock is owned by hedge funds and other institutional investors.

Elevance Health News Summary

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Elevance reported Q2 results ahead of expectations, with management saying performance improved across its diversified portfolio and that it is raising 2026 adjusted EPS guidance to at least $27.00. Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance
• Positive Sentiment: Medical cost management appears to be improving, with lower medical costs in some plans helping lift profits and supporting a better outlook for the rest of the year. Elevance raises annual profit forecast on better medical cost management
• Positive Sentiment: The company also benefited from higher sales in the quarter, which helped offset pressure from a higher benefit-expense ratio. Elevance Health Raises Earnings Outlook on Higher Sales
• Positive Sentiment: Truist raised its price target on ELV to $475 and reiterated a buy rating, signaling increased analyst confidence after the earnings update. Elevance Health (NYSE:ELV) Price Target Raised to $475.00 at Truist Financial
• Neutral Sentiment: Pre-earnings commentary had flagged possible pressure from weaker Health Benefits results and higher benefit expenses, but those concerns were at least partly offset by the reported quarter. Will Health Benefits Weakness Drag Elevance’s Q2 Earnings?

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on ELV shares. Wall Street Zen lowered shares of Elevance Health from a “buy” rating to a “hold” rating in a research note on Sunday. Robert W. Baird raised their price target on Elevance Health from $317.00 to $331.00 and gave the stock a “neutral” rating in a report on Thursday, April 23rd. Sanford C. Bernstein lifted their price target on Elevance Health from $424.00 to $482.00 and gave the company an “outperform” rating in a research report on Thursday, July 2nd. Weiss Ratings upgraded Elevance Health from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, May 18th. Finally, Guggenheim raised their target price on Elevance Health from $396.00 to $399.00 and gave the stock a “buy” rating in a research note on Friday, April 24th. Fifteen investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $435.05.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.